# Inquis Medical, Inc.

> Inquis Medical is a Silicon Valley medical device company founded in 2020 by serial medtech entrepreneurs Vahid and Mojgan Saadat. Its flagship AVENTUS Precision Thrombectomy System removes blood clots from patients with pulmonary embolism (PE) and deep vein thrombosis (DVT), using proprietary TrueClot tissue-sensing technology that gives physicians real-time feedback to distinguish blood, clot, and vessel wall while minimizing blood loss through autologous blood reinfusion. Backed by $115M in total funding including a $75M Series C in January 2026, the company is scaling nationwide commercial adoption after winning FDA 510(k) clearance for PE in 2025.

- **Founded:** 2020
- **Headquarters:** Menlo Park, California, United States
- **Founders:** Vahid Saadat (Co-Founder & Co-CEO), Mojgan Saadat (Co-Founder & Co-CEO)
- **Team size:** ~80 employees
- **Products:** AVENTUS Precision Thrombectomy System, AVENTUS Introducer Sheath, AVENTUS Clot Management System
- **Notable:** FDA 510(k) clearance for the AVENTUS Thrombectomy System for treatment of pulmonary embolism (2025), expanding from prior peripheral vasculature indication, AVENTUS pivotal trial met primary safety and efficacy endpoints with zero device-related major adverse events at 48 hours in 130 intermediate-risk PE patients, Mean 0.47 reduction in RV/LV ratio at 48 hours post-procedure

## Products & services

- **AVENTUS Precision Thrombectomy System** — Flagship mechanical thrombectomy platform for removing clot burden in patients with pulmonary embolism (PE) and deep vein thrombosis (DVT), featuring proprietary TrueClot tissue-sensing technology that provides real-time feedback to differentiate between blood, clot, and vessel wall.
- **AVENTUS Introducer Sheath** — Access sheath designed to minimize blood loss during insertion of endovascular devices.
- **AVENTUS Clot Management System** — Autologous blood reinfusion system that returns a patient's own blood during the thrombectomy procedure, reducing blood loss.

## Achievements

- FDA 510(k) clearance for the AVENTUS Thrombectomy System for treatment of pulmonary embolism (2025), expanding from prior peripheral vasculature indication
- AVENTUS pivotal trial met primary safety and efficacy endpoints with zero device-related major adverse events at 48 hours in 130 intermediate-risk PE patients
- Mean 0.47 reduction in RV/LV ratio at 48 hours post-procedure
- 68.9% of patients discharged from the ICU in under 24 hours (mean ICU stay 0.8 days)
- Raised $75M Series C in January 2026, bringing total funding to $115M
- Trial results published in the peer-reviewed journal JSCAI and presented at SCAI 2025 Late-Breaking Clinical Trial Session

## Latest updates

- **2026-01** — Announced $75 million Series C financing to scale nationwide commercial adoption of the AVENTUS Thrombectomy System and advance its next-generation product pipeline.
- **2025-06** — AVENTUS Thrombectomy System received FDA 510(k) clearance for treatment of pulmonary embolism.
- **2025-05** — AVENTUS trial results presented as a late-breaking clinical trial at SCAI 2025 and published in JSCAI, showing zero device-related MAEs and strong efficacy.

## Links

- Website: https://inquismedical.com
- LinkedIn: https://www.linkedin.com/company/inquis-medical
- Twitter/X: https://x.com/Inquismedical
- YouTube: https://youtube.com/@inquis.medical

---

Profile page: https://yespress.io/inquis-medical-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-11